GPR114 | G protein-coupled receptor 114 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR171 | G protein-coupled receptor 171 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR174 | G protein-coupled receptor 174 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR18 | G protein-coupled receptor 18 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR31 | G protein-coupled receptor 31 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GRAP | GRB2-related adaptor protein | Plasma proteins
| | | | | Tissue enhanced |
GRAP2 | GRB2-related adaptor protein 2 | Plasma proteins
| | | | | Tissue enhanced |
GRAPL | GRB2-related adaptor protein-like | | | | | | Tissue enhanced |
GTSCR1 | Gilles de la Tourette syndrome chromosome region, candidate 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
GZMA | Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
GZMK | Granzyme K (granzyme 3; tryptase II) | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
GZMM | Granzyme M (lymphocyte met-ase 1) | Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
HAPLN3 | Hyaluronan and proteoglycan link protein 3 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
HIST1H1B | Histone cluster 1, H1b | Plasma proteins
| | | | | Tissue enhanced |
HIST1H2BM | Histone cluster 1, H2bm | | | | | | Tissue enhanced |
ICOS | Inducible T-cell co-stimulator | CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
IFNG | Interferon, gamma | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IKZF1 | IKAROS family zinc finger 1 (Ikaros) | Cancer-related genes Disease related genes Predicted membrane proteins Transcription factors
| | | | | Tissue enhanced |
IKZF3 | IKAROS family zinc finger 3 (Aiolos) | Transcription factors
| | | | | Tissue enhanced |
IL12RB1 | Interleukin 12 receptor, beta 1 | CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IL21R | Interleukin 21 receptor | Cancer-related genes CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
IL2RG | Interleukin 2 receptor, gamma | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
IL7R | Interleukin 7 receptor | Cancer-related genes CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IRF8 | Interferon regulatory factor 8 | Disease related genes Plasma proteins Transcription factors
| | | | | Tissue enhanced |
ITK | IL2-inducible T-cell kinase | Cancer-related genes Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
JAK3 | Janus kinase 3 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
KB-1980E6.3 | Uncharacterized protein | | | | | | Tissue enhanced |
KBTBD8 | Kelch repeat and BTB (POZ) domain containing 8 | | | | | | Tissue enhanced |
KIAA0125 | KIAA0125 | | | | | | Tissue enhanced |
KIAA0226L | KIAA0226-like | | | | | | Tissue enhanced |
KLHL6 | Kelch-like family member 6 | | | | | | Tissue enhanced |
KLRK1 | Killer cell lectin-like receptor subfamily K, member 1 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LAIR2 | Leukocyte-associated immunoglobulin-like receptor 2 | CD markers Predicted secreted proteins
| | | | | Tissue enhanced |
LCK | Lymphocyte-specific protein tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
LCN8 | Lipocalin 8 | | | | | | Tissue enhanced |
LEF1 | Lymphoid enhancer-binding factor 1 | Plasma proteins Transcription factors
| | | | | Tissue enhanced |
LILRA4 | Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 4 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LIMD2 | LIM domain containing 2 | | | | | | Tissue enhanced |
LRMP | Lymphoid-restricted membrane protein | Predicted membrane proteins
| | | | | Tissue enhanced |
LTA | Lymphotoxin alpha | Cancer-related genes Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
LY86 | Lymphocyte antigen 86 | Predicted secreted proteins
| | | | | Tissue enhanced |
LY9 | Lymphocyte antigen 9 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
MAP4K1 | Mitogen-activated protein kinase kinase kinase kinase 1 | Enzymes
| | | | | Tissue enhanced |
MDS2 | Myelodysplastic syndrome 2 translocation associated | Disease related genes
| | | | | Tissue enhanced |
MIXL1 | Mix paired-like homeobox | Transcription factors
| | | | | Tissue enhanced |
MMP9 | Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MYBL1 | V-myb avian myeloblastosis viral oncogene homolog-like 1 | Plasma proteins Transcription factors
| | | | | Tissue enhanced |
MYBL2 | V-myb avian myeloblastosis viral oncogene homolog-like 2 | Cancer-related genes Transcription factors
| | | | | Tissue enhanced |
NCR3 | Natural cytotoxicity triggering receptor 3 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |